Efficacy comparisons between Cipralex and Serotonin Noradrenaline Reuptake inhibitors (venlafaxine and duloxetine)

• Data were pooled from four randomised controlled trials (two with duloxetine, two with venlafaxine) previously published individually
• Included outpatients (18–85 years of age) with moderate-to-severe major depressive disorder (MDD)
• The primary efficacy parameter in all four trials was mean change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score

Greater mean reduction in MADRS total score from baseline and significantly higher response and remission rates versus SNRIs in all patients (ref.1)

Escitalopram demonstrates even more pronounced efficacy in the severely depressed patient subset (those with a baseline MADRS score of 30 or greater) (ref.1)

Significantly fewer discontinuations with Cipralex due to adverse events were also observed. The difference was 12% versus 5%. (ref.1)

References:

1. Kornstein SG et al. CNS Spectr 2009;14(6):326-333